IQVIA Holdings Inc. $IQV Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in IQVIA by 21.3%, selling 31,862 shares and retaining 117,764 shares worth about $26.64 million.
• Other institutions increased exposure—Boston Partners opened a new roughly $676.7 million position and AQR boosted its holding by 130.2%—leaving hedge funds and institutions with about 89.62% ownership of IQVIA.
• Analysts maintain a consensus "Buy" rating with an average price target of $226.63; the stock trades near $160.70 after a recent earnings beat and FY2026 guidance of 12.55–12.85 EPS.

Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 21.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 117,764 shares of the medical research company's stock after selling 31,862 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.07% of IQVIA worth $26,636,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Boston Partners purchased a new position in IQVIA during the third quarter worth $676,698,000. AQR Capital Management LLC boosted its stake in shares of IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company's stock valued at $245,099,000 after acquiring an additional 879,701 shares during the last quarter. Citigroup Inc. increased its position in IQVIA by 108.2% during the 3rd quarter. Citigroup Inc. now owns 915,183 shares of the medical research company's stock worth $173,830,000 after purchasing an additional 475,557 shares in the last quarter. Cantillon Capital Management LLC raised its stake in IQVIA by 27.3% in the 3rd quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company's stock valued at $366,002,000 after purchasing an additional 413,256 shares during the last quarter. Finally, Invesco Ltd. raised its stake in IQVIA by 15.3% in the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company's stock valued at $526,891,000 after purchasing an additional 367,204 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on IQV. Royal Bank Of Canada began coverage on shares of IQVIA in a report on Tuesday, March 3rd. They set an "outperform" rating and a $221.00 price target for the company. Citigroup decreased their target price on shares of IQVIA from $230.00 to $200.00 and set a "neutral" rating on the stock in a research report on Friday, February 6th. UBS Group lowered their target price on shares of IQVIA from $280.00 to $240.00 and set a "buy" rating for the company in a research note on Friday, February 6th. Evercore reissued an "outperform" rating and set a $185.00 price target on shares of IQVIA in a research note on Wednesday, April 8th. Finally, BMO Capital Markets set a $250.00 price objective on IQVIA in a report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $226.63.

IQVIA Stock Performance

Shares of IQV stock opened at $160.70 on Friday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market capitalization of $27.27 billion, a price-to-earnings ratio of 20.45, a price-to-earnings-growth ratio of 1.74 and a beta of 1.39. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a 50 day moving average price of $170.12 and a 200 day moving average price of $203.01.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to analysts' expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.5 EPS for the current year.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.